Zhu Wei, Zhou Li, Qian Jia-Qi, Qiu Tian-Zhu, Shu Yong-Qian, Liu Ping
Wei Zhu, Li Zhou, Jia-Qi Qian, Tian-Zhu Qiu, Yong-Qian Shu, Ping Liu, Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
World J Clin Oncol. 2014 Feb 10;5(1):19-27. doi: 10.5306/wjco.v5.i1.19.
Brain metastases from solid tumours are associated with poor prognosis despite aggressive treatment. Temozolomide can be used for the treatment of glioblastoma multiforme as well as melanoma. It has also been shown to have activity in patients with brain metastases from various malignancies, since it can cross the blood-brain barrier. To better understand the efficacy of temozolomide in the treatment of brain metastases, we carried out a review of 21 published clinical trials to determine whether temozolomide would benefit patients with brain metastases from solid tumours. Information regarding complete response, partial response, stable disease, objective response and objective response rate were collected to assess clinical outcomes. A modest therapeutic effect was observed when temozolomide was used as a single agent, however, the combination of temozolomide with whole-brain radiotherapy and/or other anticancer drugs exhibited encouraging activity. Thus, future high quality studies are warranted to confirm our findings.
尽管进行了积极治疗，但实体瘤脑转移的预后仍然很差。替莫唑胺可用于治疗多形性胶质母细胞瘤以及黑色素瘤。由于它可以穿过血脑屏障，因此也已证明其对各种恶性肿瘤脑转移患者具有活性。为了更好地了解替莫唑胺治疗脑转移的疗效，我们对21项已发表的临床试验进行了综述，以确定替莫唑胺是否会使实体瘤脑转移患者受益。收集了有关完全缓解、部分缓解、病情稳定、客观缓解和客观缓解率的信息，以评估临床结果。当替莫唑胺作为单一药物使用时，观察到适度的治疗效果，然而，替莫唑胺与全脑放疗和/或其他抗癌药物联合使用时表现出令人鼓舞的活性。因此，有必要进行未来的高质量研究来证实我们的发现。
